Results 1 to 10 of about 97,768,729 (189)

Iduronate-2-sulfatase interactome: validation by yeast two-hybrid assay [PDF]

open access: yesHeliyon, 2022
Background: Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a rare X-linked recessive disease caused by a deficiency of the lysosomal enzyme iduronate-2-sulfatase (IDS), which activates intracellular accumulation of ...
Eliana Benincore-Flórez   +6 more
doaj   +7 more sources

Insights into Hunter syndrome from the structure of iduronate-2-sulfatase [PDF]

open access: yesNature Communications, 2017
Hunter syndrome is a lysosomal storage disease caused by mutations in the enzyme iduronate-2-sulfatase (IDS). Here, the authors present the IDS crystal structure and give mechanistic insights into mutations that cause Hunter syndrome.
Mykhaylo Demydchuk   +7 more
doaj   +11 more sources

Identification of the iduronate-2-sulfatase proteome in wild-type mouse brain [PDF]

open access: yesHeliyon, 2019
Iduronate-2-sulfatase (IDS) is a lysosomal enzyme involved in the metabolism of the glycosaminoglycans heparan (HS) and dermatan (DS) sulfate. Mutations on IDS gene produce mucopolysaccharidosis II (MPS II), characterized by the lysosomal accumulation of
Carolina Cardona   +8 more
doaj   +5 more sources

In vivo brain delivery of BBB-enabled iduronate 2-sulfatase in rats [PDF]

open access: yesFluids and Barriers of the CNS
Background Iduronate-2-sulfatase (IDS) deficiency (MPS II; Hunter syndrome) is a disorder that exhibits peripheral and CNS pathology. The blood brain barrier (BBB) prevents systemic enzyme replacement therapy (ERT) from alleviating CNS pathology.
Will J. Costain   +16 more
doaj   +4 more sources

Production of active human iduronate-2-sulfatase (IDS) enzyme in Nicotiana benthamiana [PDF]

open access: yesScientific Reports
Many strategies have been developed to produce high levels of biologically active recombinant proteins in plants for biopharmaceutical purposes. However, the production of an active form of human iduronate-2-sulfatase (hIDS) for the treatment of Hunter ...
Md Hasif Sinha   +5 more
doaj   +3 more sources

Quantification of the enzyme activities of iduronate-2-sulfatase, N-acetylgalactosamine-6-sulfatase and N-acetylgalactosamine-4-sulfatase using liquid chromatography-tandem mass spectrometry [PDF]

open access: yesMolecular Genetics and Metabolism Reports, 2018
Mucopolysaccharidosis (MPS) is a genetic disorder characterized by the accumulation of glycosaminoglycans in the body. Of the multiple MPS disease subtypes, several are caused by defects in sulfatases.
Ryuichi Mashima   +3 more
doaj   +3 more sources

A novel mucopolysaccharidosis type II mouse model with an iduronate-2-sulfatase-P88L mutation [PDF]

open access: yesScientific Reports, 2023
Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disorder characterized by an accumulation of glycosaminoglycans (GAGs), including heparan sulfate, in the body.
Ryuichi Mashima   +4 more
doaj   +2 more sources

Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Iduronate-2-Sulfatase in Rhesus Macaques [PDF]

open access: yesMolecular Therapy: Methods & Clinical Development, 2018
Hunter syndrome is an X-linked recessive disease caused by deficiency of the lysosomal enzyme iduronate-2-sulfatase. The severe form of this progressive, systemic, and neurodegenerative disease results in loss of cognitive skills and early death. Several
Juliette Hordeaux   +7 more
doaj   +2 more sources

Frequency of iduronate-2-sulfatase gene variants detected in newborn screening for mucopolysaccharidosis type II in Japan [PDF]

open access: yesMolecular Genetics and Metabolism Reports, 2023
Mucopolysaccharidosis II (MPS II) is an X-linked, recessive, inborn metabolic disorder caused by defects in iduronate-2-sulfatase (IDS). The age at onset, disease severity, and rate of progression vary significantly among patients.
Yusuke Hattori   +8 more
doaj   +2 more sources

Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome [PDF]

open access: yesJCI Insight, 2021
Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disorder caused by deficiency of the iduronate-2-sulfatase (IDS) enzyme, resulting in cellular accumulation of glycosaminoglycans (GAGs) throughout the body.
Annie Arguello   +27 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy